Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma

被引：1

作者：

Mizumura, Kenji ^{[1
]}

Gon, Yasuhiro ^{[1
]}

Harada, Norihiro ^{[2
,3
]}

Yamada, Shiho ^{[1
]}

Fukuda, Asami ^{[1
]}

Ozoe, Ryosuke ^{[1
]}

Maruoka, Shuichiro ^{[1
]}

Abe, Sumiko ^{[2
,3
]}

Takahashi, Kazuhisa ^{[2
,3
]}

Tanaka, Akihiko ^{[4
]}

Sagara, Hironori ^{[4
]}

Akamatsu, Taisuke ^{[5
]}

Shirai, Toshihiro ^{[5
]}

Masaki, Katsunori ^{[6
]}

Fukunaga, Koichi ^{[6
]}

Kobayashi, Konomi ^{[7
]}

Nagase, Hiroyuki ^{[7
]}

Miyahara, Nobuaki ^{[8
]}

Kanehiro, Arihiko ^{[9
]}

Kitamura, Noboru ^{[10
]}

Sugihara, Naruhiko ^{[10
]}

Kumasawa, Fumio ^{[1
,11
]}

Terada-Hirashima, Junko ^{[12
]}

Hojo, Masayuki ^{[12
]}

Chibana, Kazuyuki ^{[13
]}

Tagaya, Etsuko ^{[14
]}

机构：

[1] Nihon Univ, Sch Med, Dept Internal Med, Div Resp Med, 30-1 Oyaguchi Kami Cho,Itabashi Ku, Tokyo 1738610, Japan

[2] Juntendo Univ, Fac Med, Dept Resp Med, Tokyo, Japan

[3] Juntendo Univ, Grad Sch Med, Tokyo, Japan

[4] Showa Univ, Sch Med, Dept Med, Div Resp Med & Allergol, Tokyo, Japan

[5] Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka, Japan

[6] Keio Univ, Sch Med, Dept Med, Div Pulm Med, Tokyo, Japan

[7] Teikyo Univ, Sch Med, Dept Med, Div Resp Med & Allergol, Tokyo, Japan

[8] Okayama Univ, Dept Med Technol, Acad Field Hlth Sci, Okayama, Japan

[9] St Francis Himeji St Marys Hosp, Social Med Corp Fdn, Himeji, Hyogo, Japan

[10] Jinyu Clin, Tokyo, Japan

[11] Akabane Cent Gen Hosp, Div Resp Med, Tokyo, Japan

[12] Natl Ctr Global Hlth & Med, Dept Resp Med, Tokyo, Japan

[13] Dokkyo Med Univ, Sch Med, Dept Pulm Med & Clin Immunol, Mibu, Tochigi, Japan

[14] Tokyo Womens Med Univ, Dept Resp Med, Tokyo, Japan

来源：

ALLERGOLOGY INTERNATIONAL | 2025年 / 74卷 / 01期

关键词：

Asthma; Dupilumab; Eosinophil; Fractional exhaled nitric oxide; Sputum; TO-SEVERE ASTHMA; VALIDATION; HYPERSECRETION; EFFICACY; AIR;

D O I：

10.1016/j.alit.2024.08.005

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Background: The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and identify predictors of its effectiveness in real-world settings using two type-2 biomarkers: FeNO concentration and blood eosinophil count. Methods: This prospective multicenter study included 103 patients with severe asthma. Exacerbations and respiratory functions were monitored for 24 weeks. Asthma control was evaluated using the Asthma Control Questionnaire-5. Clinical symptoms and their impact on cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q). Subgroup analyses of type-2 biomarkers were conducted based on FeNO levels and blood eosinophil counts at baseline. Results: Treatment with dupilumab led to a reduction in exacerbations and enhancement in asthma control, FEV1, and CASA-Q scores. FEV1 improvement was correlated with enhancement in the sputum domain of the CASA-Q. Patients exhibiting elevated FeNO levels and blood eosinophil counts demonstrated more significant enhancements in FEV1. CASA-Q sputum domain scores were significantly higher in the group with elevated eosinophil counts. Regression analysis revealed that FeNO levels and blood eosinophil counts are significant predictors of FEV1 improvement, with blood eosinophil counts also predicting sputum improvement in patients treated with dupilumab. Conclusions: Type-2 biomarkers may act as indicators of improvement in FEV1 and sputum outcomes among patients with severe asthma undergoing dupilumab treatment in real-world settings. (c) 2024 Japanese Society of Allergology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：144 / 155

页数：12

共 50 条

[1] Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
Numata, Takanori
Araya, Jun
Miyagawa, Hanae
Okuda, Keitaro
Takekoshi, Daisuke
Hashimoto, Mitsuo
Minagawa, Shunsuke
Ishikawa, Takeo
Hara, Hiromichi
Kuwano, Kazuyoshi
JOURNAL OF ASTHMA AND ALLERGY, 2022, 15 : 395 - 405
[2] Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study
Bult, L.
Thelen, J. C.
Rauh, S. P.
in't Veen, J. C. C. M.
Braunstahl, G. J.
RESPIRATORY MEDICINE, 2024, 231
[3] Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world observational study
Bult, Lotte
Thelen, J. C.
In't Veen, J. C. C. M.
Braunstahl, G. J.
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[4] Assessing biomarkers in a real-world severe asthma study (ARIETTA)
Buhl, Roland
Korn, Stephanie
Menzies-Gow, Andrew
Aubier, Michel
Chapman, Kenneth R.
Canonica, Giorgio W.
Picado, Cesar
Martin, Nicolas
Escobar, Ramon Aguiar
Korom, Stephan
Hanania, Nicola A.
RESPIRATORY MEDICINE, 2016, 115 : 7 - 12
[5] Type-2 biomarkers and efficacy of dupilumab in children with asthma
Wark, P.
Bacharier, L.
Jackson, D.
Pavord, I
Maspero, J.
Fiocchi, A.
Mao, X.
Jacob-Nara, J.
Deniz, Y.
Laws, E.
Mannent, L.
Akinlade, B.
Staudinger, H.
Lederer, D.
Moody, J.
Hardin, M.
RESPIROLOGY, 2023, 28 : 132 - 133
[6] Biomarkers for predicting type 2-high and uncontrolled asthma in real-world practice
Woo, Seong-Dae
Park, Hee Sun
Jang, Jae-Hyuk
Lee, Youngsoo
Yang, Eun-Mi
Ban, Ga-Young
Kim, Seung-Hyun
Shin, Yoo Seob
Ye, Young-Min
Park, Hae-Sim
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (02) : 209 - 216.e2
[7] Biomarkers for predicting type 2-high and uncontrolled asthma in real-world practice
Woo, S. D.
Park, H. S.
ALLERGY, 2023, 78
[8] REAL-WORLD EFFECTIVENESS OF DUPILUMAB IN ASTHMA: FINDINGS FROM THE US ADVANTAGE STUDY
Blaiss, M.
Bleecker, E.
Jacob-Nara, J.
Duh, M.
Stanford, R.
Wang, Z.
Soler, X.
Nair, R.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S38 - S38
[9] Real-world effectiveness of dupilumab on oral corticosteroid use in asthma
Wark, P.
Pawar, A.
Blaiss, M.
Modena, B.
Khan, A.
Gomez, De Prado L.
Pandit-Abid, N.
Radwan, A.
Moody, J.
Jacob-Nara, J.
RESPIROLOGY, 2023, 28 : 87 - 88
[10] Real-world effectiveness of dupilumab vs benralizumab and vs mepolizumab in severe asthma: The EU-ADVANTAGE study
Virchow, J. Christian
Canonica, Giorgio W.
Bourdin, Arnaud
Jacob-Nara, Juby
Borsos, Kinga
Stanford, Richard H.
Pandit-Abid, Nami
Wang, Zhixiao
Soliman, Mena
Huynh, Lynn
Kalia, Sarah
Cheng, Wendy
EUROPEAN RESPIRATORY JOURNAL, 2024, 64

← 1 2 3 4 5 →